Understanding how Non-Small Cell Lung Cancer spreads to the brain's protective layers
Elucidating mechanisms underlying NSCLC progression to leptomeningeal disease
This study is looking at how Non-Small Cell Lung Cancer can spread to the brain and cause serious problems, especially in patients with certain genetic changes who haven't responded to regular treatments, and it hopes to find new ways to help these patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10993288 on NIH RePORTER |
What this research studies
This research investigates how Non-Small Cell Lung Cancer (NSCLC) progresses to a severe condition known as leptomeningeal disease (LMD), which affects the central nervous system. The study aims to uncover the biological mechanisms that allow cancer cells to invade the protective layers surrounding the brain, particularly in patients with specific genetic mutations who have become resistant to standard treatments. By examining the interactions between cancer cells and the brain's environment, the research seeks to identify potential targets for new therapies. Patients with a history of brain metastases or those with EGFR-mutant NSCLC may find this research particularly relevant.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with Non-Small Cell Lung Cancer, especially those with EGFR mutations and a history of brain metastases.
Not a fit: Patients with other types of lung cancer or those without central nervous system involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic and treatment options for patients with leptomeningeal disease.
How similar studies have performed: Previous research has shown promising results in understanding cancer metastasis, but the specific mechanisms of leptomeningeal disease progression remain largely untested.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Kandigian, Savannah Elizabeth — Yale University
- Study coordinator: Kandigian, Savannah Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.